60 Degrees Pharmaceuticals (NASDAQ:SXTP) Stock Crosses Above Fifty Day Moving Average – Should You Sell?

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) passed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $1.00 and traded as high as $1.02. 60 Degrees Pharmaceuticals shares last traded at $1.01, with a volume of 71,686 shares changing hands.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Monday, September 21st. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $13.85.

60 Degrees Pharmaceuticals Price Performance

The company has a market capitalization of $3.56 million, a P/E ratio of -0.21 and a beta of 2.47. The business’s 50-day moving average price is $1.00 and its two-hundred day moving average price is $1.77.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.16). The company had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.20 million. Research analysts expect that 60 Degrees Pharmaceuticals Inc. will post -3.31 earnings per share for the current fiscal year.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for tropical and infectious diseases. The company’s work centers on treatments and preventive therapies for conditions that affect travelers, military personnel and populations in regions where infectious diseases are prevalent.

Its lead product is Arakoda (tafenoquine), an oral prescription medicine approved by the U.S. Food and Drug Administration in 2018 for the prevention of malaria in adults.